Cat. No. | Product name | CAS No. |
DC1030 |
Regorafenib (BAY73-4506,Fluoro-Sorafenib)
Featured
Regorafenib (BAY 73-4506, Fluoro-Sorafenib) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, respectively. |
755037-03-7 |
DC10463 |
Repotrectinib(TPX-005)
Featured
Repotrectinib(TPX-005) is a multi-target macrocycle inhibitor of anaplastic lymphoma kinase (ALK), c-ros proto-oncogene 1 receptor tyrosine kinase (ROS1), and neurotrophic tyrosine kinase receptor (TRK) |
1802220-02-5 |
DC7261 |
Resminostat hydrochloride (4SC-201)
Resminostat(RAS2410; 4SC-201) is a potent inhibitor of HDAC1/3/6(IC50=43-72 nM); less potent to HDAC8 with IC50 of 877 nM. |
1187075-34-8 |
DC7265 |
Rigosertib
Featured
Rigosertib (ON-01910) is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM; shows 30-fold greater selectivity against PLK2 and no activity to PLK3. |
1225497-78-8 |
DC8215 |
RO4929097
Featured
RO4929097 is a γ secretase inhibitor with IC50 of 4 nM, inhibiting cellular processing of Aβ40 and Notch with EC50 of 14 nM and 5 nM, respectively. |
847925-91-1 |
DC7489 |
RO5126766(CH5126766)
RO5126766(CH5126766) is a Raf/MEK dual kinase inhibitor. |
946128-88-7 |
DC12353 |
Roniciclib (BAY 1000394)
Roniciclib is an orally bioavailable pan-cyclin dependent kinase (CDK) inhibitor, with IC50s of 5-25 nM for CDK1, CDK2, CDK3, CDK4, CDK7 and CDK9. |
1223498-69-8 |
DC4124 |
ROSCOVITINE(Seliciclib)
Featured
Roscovitine (Seliciclib, CYC202, R-roscovitine) is a potent and selective CDK inhibitor for Cdc2/cyclin B, CDK2/cyclin A, CDK2/cyclin E and CDK5/p53 with IC50 of 0.65 μM, 0.7 μM, 0.7 μM and 0.16 μM, respectively. |
186692-46-6 |
DC10036 |
RRx-001
Featured
RRx-001 is a novel epigenetic modulator with potential radiosensitizing activity. It inhibits glucose 6-phosphate dehydrogenase(G6PD) in human tumor cells, binds hemoglobin and drives RBC-mediated redox reactions under hypoxia. |
925206-65-1 |
DC5151 |
Rucaparib phosphate (AG-14699, PF-01367338)
Featured
Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with Ki of 1.4 nM with binding affinity to nine PARP domains. Phase 1/2. |
459868-92-9 |
DC8464 |
Rucaparib(AG-014447)
Featured
Rucaparib inactivates PARP activity in cells with homologous recombination DNA repair pathway mutations at LC50 values ranging from 1.3-5.5 μM. |
283173-50-2 |
DC4230 |
Ruxolitinib (INCB018424)
Featured
Ruxolitinib is a potent ATP mimetic that inhibits both JAK1 and JAK2 with IC50 values of 2.7 and 4.5 nM, respectively and is relatively less selective for JAK3 (IC50 = 322 nM). |
941678-49-5 |
DC8309 |
Ruxolitinib Phosphate
Featured
Ruxolitinib Phosphate is a potent and selective Janus kinase (JAK1, IC50 = 5.9 nM and JAK2, IC50 = 5.7 nM) inhibitor. |
1092939-17-7 |
DC7762 |
RX-3117
Featured
RX-3117 is an orally available and potent DNA synthesis inhibitor with potential antineoplastic activity. |
865838-26-2 |
DC10479 |
RX518(CK-101:EGFR-IN-3)
Featured
RX518(CK-101) is an orally available third-generation and selective inhibitor of certain epidermal growth factor receptor (EGFR) activating mutations. |
1660963-42-7 |
DC11265 |
S49076 (hydrochloride)
Featured
S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab. |
1265966-31-1 |
DC10071 |
S49076
Featured
S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3 with IC50 values below 20 nM. |
1265965-22-7 |
DC12279 |
S55746 hydrochloride (BLC201 (hydrochloride))
S55746 hydrochloride is a potent, orally active and selective BCL-2 inhibitor, with Kis and Kds of 1.3 nM, 520 nM and 3.9 nM, 186 nM for BCL-2 and BCL-XL, respectively. S55746 hydrochloride has antitumor activity. |
1448525-91-4 |
DC12163 |
S55746 (BLC201)
Featured
S55746 (BLC201) is a potent, orally active and selective BCL-2 inhibitor, with a Ki of 1.3 nM and a Kd of 3.9 nM. S55746 (BLC201) has antitumor activity with low toxicity[1]. |
1448584-12-0 |
DC10137 |
S63845
Featured
S63845 is a potent and selective myeloid cell leukemia 1 (MCL1) inhibitor; binds human MCL1 with a Kd of 0.19 nM. |
1799633-27-4 |
DC10444 |
Sapacitabine (CYC682)
Featured
Sapacitabine is an orally bioavailable pyrimidine analogue prodrug with potential antineoplastic activity. |
151823-14-2 |
DC7078 |
AZD-8931(Sapitinib)
Featured
Sapitinib(AZD8931) is a reversible, ATP competitive inhibitor of EGFR, ErbB2 and ErbB3 with IC50 of 4 nM, 3 nM and 4 nM respectively. |
848942-61-0 |